Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$2.6 million.

  • ImmunoTech's Change in Account Payables fell 41767.61% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 14421.75%. This contributed to the annual value of -$60000.0 for FY2024, which is 10098.91% down from last year.
  • Latest data reveals that ImmunoTech reported Change in Account Payables of -$2.6 million as of Q3 2025, which was down 41767.61% from $353000.0 recorded in Q2 2025.
  • Over the past 5 years, ImmunoTech's Change in Account Payables peaked at $3.7 million during Q4 2023, and registered a low of -$2.6 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Account Payables was $561000.0 (2025), whereas its average is $395454.5.
  • Data for ImmunoTech's Change in Account Payables shows a peak YoY increase of 35241.94% (in 2025) and a maximum YoY decrease of 41767.61% (in 2025) over the last 5 years.
  • ImmunoTech's Change in Account Payables (Quarter) stood at $3.7 million in 2023, then tumbled by 96.74% to $119000.0 in 2024, then crashed by 2259.66% to -$2.6 million in 2025.
  • Its Change in Account Payables was -$2.6 million in Q3 2025, compared to $353000.0 in Q2 2025 and $561000.0 in Q1 2025.